ZURICH: Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an ...
ZURICH: Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.
The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help tumors to evade attack by the body's immune system, Roche said on Thursday .Tecentriq trailed rival immunotherapies Keytruda and Opdivo - produced by Merck and Bristol-Myers Squibb respectively - to market but has been racking up approvals.
These include approvals for niche indications such as metastatic triple-negative breast cancer. Some 15 to 20 per cent of breast cancer is triple-negative, meaning tumors lack three characteristics for which there are more treatment options. "The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great," Roche Chief Medical Officer Sandra Horning said in a statement.
Tecentriq, having steadily added approvals in new cancer indications and new geographies, is on track to surpass US$1.5 billion in annual sales in 2019, its third full year on the market.Opdivo and Keytruda, which had a two-year head start on Tecentriq, achieved sales of US$6.7 billion and US$7.2 billion respectively in 2018.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche immunotherapy Tecentriq gains European approval for breast cancerZURICH: Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an ...
Read more »
Roche immunotherapy Tecentriq gains European approval for breast cancerZURICH: Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an ...
Read more »
Oil prices gain nearly 2per cent after drop in US crude inventoriesOil prices rose nearly 2per cent on Wednesday after a larger-than-expected decline in U.S. crude stockpiles helped ease worries about weakening ...
Read more »
Hurricane Dorian gains might as it takes aim at FloridaHurricane Dorian churned in the Atlantic, picking up speed early on Thursday, fuelled by warm waters as it took aim at the U.S. coast and ...
Read more »
Singapore shares gain 0.8% on Thursday's late surgeINVESTOR sentiment continued to be heavily dependent on US-China trade developments with the local market witnessing a late surge after Beijing indicated that it does not intend to react immediately to Washington's most recent tariff increase. Read more at The Business Times.
Read more »
Seoul: Stocks gain on improved sentiment in pharma sector[SEOUL] South Korean shares closed firmer on Wednesday as investors flocked to pharmaceutical stocks following a sharp sell-off in the recent days. Read more at The Business Times.
Read more »